Treatment of diffuse large B-cell lymphoma in the elderly: regimens without anthracyclines are common and not futile

References

• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the united states, 1992-2001. Blood 2006;107:265–276.
   PubMed Web of Science ®Google Scholar
• Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220–241.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24: 3121–3127.
   PubMed Web of Science ®Google Scholar
• Grann VR, Hershman D, Jacobson JS, et al. Outcomes and diffusion of doxorubicin-based chemotherapy among elderly patients with aggressive non-hodgkin lymphoma. Cancer 2006;107:1530–1541.
   PubMed Web of Science ®Google Scholar
• Link BK, Brooks J, Wright K, et al. Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines. Leuk Lymphoma 2011;52:994–1002.
   PubMed Web of Science ®Google Scholar
• van de Schans SA, Wymenga AN, van Spronsen DJ, et al. Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma. Ann Oncol 2012;23:1280–1286.
   PubMed Web of Science ®Google Scholar
• Keating NL, Landrum MB, Lamont EB, et al. Quality of care for older patients with cancer in the veterans health administration versus the private sector: a cohort study. Ann Intern Med 2011;154: 727–736.
   PubMed Web of Science ®Google Scholar
• Maartense E, Hermans J, Kluin-Nelemans JC, et al. Elderly patients with non-Hodgkin's lymphoma: population-based results in the Netherlands. Ann Oncol 1998;9:1219–1227.
   PubMed Web of Science ®Google Scholar
• Hasselblom S, Stenson M, Werlenius O, et al. Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era. Leuk Lymphoma 2012;53:394–399.
   PubMed Web of Science ®Google Scholar
• Mori M, Niitsu N, Takagi T, et al. Reduced-dose chop therapy for elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2001;41:359–366.
   PubMed Web of Science ®Google Scholar
• Potosky AL, Riley GF, Lubitz JD, et al. Potential for cancer related health services research using a linked medicare-tumor registry database. Med Care 1993;31:732–748.
   PubMed Web of Science ®Google Scholar
• Spina M, Balzarotti M, Uziel L, et al. Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Oncologist 2012;17:838–846.
   PubMed Web of Science ®Google Scholar
• Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460–468.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004;22:4302–4311.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Flinn IW, Spigel DR, et al. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma Leuk 2010;10:44–50.
   PubMed Web of Science ®Google Scholar
• Fields PA, Linch DC. Treatment of the elderly patient with diffuse large B cell lymphoma. Br J Haematol 2012;157:159–170.
   PubMed Web of Science ®Google Scholar
• Moccia A, Schaff K, Hoskins P, et al. R-CHOP with etoposide substituted for doxorubicin (R-CEOP): excellent outcome in diffuse large B cell lymphoma for patients with a contraindication to anthracyclines. Blood 2009;114(Suppl. 1): Abstract 408.
   Google Scholar
• Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40(8 Suppl.): IV-3-18.
   Web of Science ®Google Scholar
• National Cancer Institute: SEER-Medicare: Brief description of the SEER-Medicare database. Available from: http://healthservices.cancer.gov/seermedicare/overview/brief.html
   Google Scholar
• Wirth A. The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma 2007;48:2121–2136.
   PubMed Web of Science ®Google Scholar
• Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258–1267.
   PubMed Web of Science ®Google Scholar
• Nieto FJ, Coresh J. Adjusting survival curves for confounders: a review and a new method. Am J Epidemiol 1996;143:1059–1068.
   PubMed Web of Science ®Google Scholar
• Ghali WA, Quan H, Brant R, et al. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA 2001;286:1494–1497.
   PubMed Web of Science ®Google Scholar
• Soubeyran P, Khaled H, MacKenzie M, et al. Diffuse large B-cell and peripheral T-cell non-hodgkin’s lymphoma in the frail elderly: a phase II EORTC trial with a progressive and cautious treatment emphasizing geriatric assessment. J Geriatr Oncol 2011;2:36–44.
   Web of Science ®Google Scholar
• Balducci L, Beghe C. The application of the principles of geriatrics to the management of the older person with cancer. Crit Rev Oncol Hematol 2000;35:147–154.
   PubMed Web of Science ®Google Scholar
• Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to eastern cooperative oncology group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology study. J Clin Oncol 2002;20:494–502.
   PubMed Web of Science ®Google Scholar
• Soubeyran P, Fonck M, Blanc-Bisson C, et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol 2012;30:1829–1834.
   PubMed Web of Science ®Google Scholar
• Monfardini S, Basso U. Oncological causes of frailty in older cancer patients. Eur J Cancer 2007;43:1230–1231.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group. Lancet Oncol 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood 2010;116:5103–5110.
   PubMed Web of Science ®Google Scholar
• Czuczman M, Vose J, Zinzani P, et al. Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: results of an international study (NHL-003). Blood 2008;112(Suppl. 1): Abstract 268.
   Google Scholar
• Hainsworth J, Arrowsmith E, Mccleod M, et al. Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first line treatment of patients with intermediate and high-risk diffuse large B cell lymphoma (DLBCL)-preliminary analysis. Ann Oncol 2011;22(Suppl. 4): Abstract 074.
   Google Scholar
• Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690–697.
   PubMed Web of Science ®Google Scholar
• Wong BY, Dang NH. Inotuzumab ozogamicin as novel therapy in lymphomas. Expert Opin Biol Ther 2010;10:1251–1258.
   PubMed Web of Science ®Google Scholar